About Intrexon (NYSE:XON)
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Industry, Sector and Symbol
Industry Commercial physical research
Trailing P/E Ratio-17.89
Forward P/E Ratio-19.14
Sales & Book Value
Annual Sales$230.98 million
Price / Sales9.21
Price / CashN/A
Book Value$4.29 per share
Price / Book3.84
EPS (Most Recent Fiscal Year)($0.92)
Return on Equity-14.96%
Return on Assets-9.38%
Intrexon (NYSE:XON) Frequently Asked Questions
What is Intrexon's stock symbol?
Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."
How were Intrexon's earnings last quarter?
Intrexon Corp (NYSE:XON) announced its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.09. The biotechnology company earned $43.80 million during the quarter, compared to the consensus estimate of $60.43 million. Intrexon had a negative return on equity of 14.96% and a negative net margin of 57.66%. Intrexon's revenue was down 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.26) EPS. View Intrexon's Earnings History.
When is Intrexon's next earnings date?
What price target have analysts set for XON?
6 equities research analysts have issued 12 month price targets for Intrexon's stock. Their forecasts range from $17.00 to $57.00. On average, they anticipate Intrexon's stock price to reach $34.6667 in the next twelve months. View Analyst Ratings for Intrexon.
Who are some of Intrexon's key competitors?
Some companies that are related to Intrexon include Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRCIB), Sorrento Therapeutics (SRNE), National Research (NRCIA), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and HedgePath Pharmaceuticals (HPPI).
Who are Intrexon's key executives?
Intrexon's management team includes the folowing people:
- Mr. Randal J. Kirk, Chairman & CEO (Age 65)
- Mr. Rick L. Sterling, Chief Financial Officer (Age 54)
- Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)
- Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46)
Has Intrexon been receiving favorable news coverage?
Media headlines about XON stock have trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intrexon earned a news impact score of 0.03 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.10 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Intrexon's major shareholders?
Intrexon's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Third Security LLC (45.81%), Iridian Asset Management LLC CT (5.05%), BlackRock Inc. (2.03%), Summit Trail Advisors LLC (0.45%), Frontier Capital Management Co. LLC (0.41%) and UBS Group AG (0.33%). Company insiders that own Intrexon stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Institutional Ownership Trends for Intrexon.
Which institutional investors are selling Intrexon stock?
XON stock was sold by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Dimensional Fund Advisors LP, LPL Financial LLC, First Washington CORP, Synovus Financial Corp and Teacher Retirement System of Texas. View Insider Buying and Selling for Intrexon.
Which institutional investors are buying Intrexon stock?
XON stock was purchased by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Third Security LLC, Summit Trail Advisors LLC, MSD Partners L.P., Elephas Investment Management Ltd, Wellington Shields & Co. LLC, Frontier Capital Management Co. LLC and Wellington Shields Capital Management LLC. Company insiders that have bought Intrexon stock in the last two years include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Insider Buying and Selling for Intrexon.
How do I buy shares of Intrexon?
Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intrexon's stock price today?
One share of XON stock can currently be purchased for approximately $16.46.
How big of a company is Intrexon?
Intrexon has a market capitalization of $2.09 billion and generates $230.98 million in revenue each year. The biotechnology company earns $-117,010,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Intrexon employs 1,006 workers across the globe.
How can I contact Intrexon?
Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]
MarketBeat Community Rating for Intrexon (XON)MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days.